Correlation Between Morgan Stanley and Bristol Myers

Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Bristol Myers at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Bristol Myers into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Morgan Stanley and Bristol Myers Squibb, you can compare the effects of market volatilities on Morgan Stanley and Bristol Myers and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Bristol Myers. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Bristol Myers.

Diversification Opportunities for Morgan Stanley and Bristol Myers

0.95

Correlation Coefficient

Morgan Stanley  Bristol Myers

Almost no diversification

The 3 months correlation between Morgan and Bristol is 0.95. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley are associated (or correlated) with Bristol Myers. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Bristol Myers go up and down completely randomly.

Pair Corralation between Morgan Stanley and Bristol Myers

Assuming the 90 days trading horizon Morgan Stanley is expected to under-perform the Bristol Myers. In addition to that, Morgan Stanley is 1.13 times more volatile than Bristol Myers Squibb. It trades about 0.0 of its total potential returns per unit of risk. Bristol Myers Squibb is currently generating about 0.09 per unit of volatility. If you would invest  34,131  in Bristol Myers Squibb on September 25, 2024 and sell it today you would earn a total of  1,394  from holding Bristol Myers Squibb or generate 4.08% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Strong
Accuracy	100.0%
Values	Daily Returns

Morgan Stanley  vs.  Bristol Myers Squibb

Morgan Stanley

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental drivers, Morgan Stanley sustained solid returns over the last few months and may actually be approaching a breakup point.

Bristol Myers Squibb

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Bristol Myers sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Morgan Stanley and Bristol Myers

The main advantage of trading using opposite Morgan Stanley and Bristol Myers positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Bristol Myers can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will offset losses from the drop in Bristol Myers' long position.

The idea behind Morgan Stanley and Bristol Myers Squibb pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.